Type I interferon signature in systemic lupus erythematosus

Israel Medical Association Journal

Volumn 16, Issue 4, 2014, Pages 246-249

  Bezalel, Shira ^a   Guri, Keren Mahlab ^a   Elbirt, Daniel ^a   Asher, Ilan ^a   Sthoeger, Zev Moshe ^a  

^a HEBREW UNIVERSITY   (Israel)

Author keywords

Interferon signature; Interferon alpha (IFN ); Systemic lupus erythematosus (SLE)

Indexed keywords

B CELL ACTIVATING FACTOR; CD8 ANTIGEN; DOUBLE STRANDED RNA; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INTERFERON; MYELOID DIFFERENTIATION FACTOR 88; RETINOIC ACID INDUCIBLE PROTEIN I; SIFALIMUMAB; TOLL LIKE RECEPTOR;

ANTIGEN PRESENTATION; B LYMPHOCYTE; CYTOKINE PRODUCTION; CYTOTOXICITY; DISEASE ACTIVITY; DRUG EFFICACY; GENE EXPRESSION; GENOTYPE; HUMAN; INNATE IMMUNITY; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PLASMACYTOID DENDRITIC CELL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL;

ADAPTIVE IMMUNITY; ANIMALS; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, INNATE; INTERFERON TYPE I; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 84898413247     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 2006; 15 (5): 308-18.
2. Askanase A, Shum K, Mitnick H. Systemic lupus erythematosus: an overview. Soc Work Health Care 2012; 51 (7): 576-86.
3. Crow MK. Developments in the clinical understanding of lupus. Arthritis Res Ther 2009; 11 (5): 245.
4. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 2004; 75 (2): 163-89.
5. Lasfar A, Abushahba W, Balan M, Cohen-Solal KA. Interferon lambda: a new sword in cancer immunotherapy. Clin Dev Immunol 2011; 2011: 349575.
6. Ronnblom L, Eloranta ML. The interferon signature in autoimmune diseases. Curr Opin Rheumatol 2013; 25 (2): 248-53.
7. Fitzgerald-Bocarsly P, Dai J, Singh S. Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history. Cytokine Growth Factor Rev 2008; 19 (1): 3-19.
8. O'Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 2012; 36 (4): 542-50.
9. de Veer MJ, Holko M, Frevel M, et al. Functional classification of interferonstimulated genes identified using microarrays. J Leukoc Biol 2001; 69 (6): 912-20.
10. Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Sanmamed MF, Le Bon A, Melero I. Direct effects of type I interferons on cells of the immune system. Clin Cancer Res 2011; 17 (9): 2619-27.
11. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979; 301 (1): 5-8.
12. Ytterberg SR, Schnitzer TJ. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum 1982; 25 (4): 401-6.
13. Gota C, Calabrese L. Induction of clinical autoimmune disease by therapeutic interferon-alpha. Autoimmunity 2003; 36 (8): 511-18.
14. Niewold TB, Swedler WI. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin Rheumatol 2005; 24 (2): 178-81.
15. Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003; 100 (5): 2610-15.
16. Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197 (6): 711-23.
17. Ronnblom L, Alm GV, Eloranta ML. The type I interferon system in the development of lupus [Review]. Semin Immunol 2011; 23 (2): 113-21.
18. Cederblad B, Blomberg S, Vallin H, Perers A, Alm GV, Ronnblom L. Patients with systemic lupus erythematosus have reduced numbers of circulating natural interferon-alpha-producing cells. J Autoimmun 1998; 11 (5): 465-70.
19. Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL. Plasmacytoid dendritic cells (natural interferon-alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 2001; 159 (1): 237-43.
20. Tucci M, Quatraro C, Lombardi L, Pellegrino C, Dammacco F, Silvestris F. Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18. Arthritis Rheum 2008; 58 (1): 251-62.
21. Jin O, Kavikondala S, Mok MY, et al. Abnormalities in circulating plasmacytoid dendritic cells in patients with systemic lupus erythematosus. Arthritis Res Ther 2010; 12 (4): R137.
22. Crispin JC, Tsokos GC. Interleukin-17-producing T cells in lupus. Curr Opin Rheumatol 2010; 22 (5): 499-503.
23. Graham RR, Kozyrev SV, Baechler EC, et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 2006; 38 (5): 550-5.
24. Salloum R, Franek BS, Kariuki SN, et al. Genetic variation at the IRF7/ PHRF1 locus is associated with autoantibody profile and serum interferonalpha activity in lupus patients. Arthritis Rheum 2010; 62 (2): 553-61.
25. Remmers EF, Plenge RM, Lee AT, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007; 357 (10): 977-86.
26. Pothlichet J, Niewold TB, Vitour D, Solhonne B, Crow MK, Si-Tahar M. A loss-of-function variant of the antiviral molecule MAVS is associated with a subset of systemic lupus patients. EMBO Mol Med 2011; 3 (3): 142-52.
27. Feng X, Wu H, Grossman JM, et al. Association of increased interferoninducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54 (9): 2951-62.
28. Rose T, Grutzkau A, Hirseland H, et al. IFNα and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus. Ann Rheum Dis 2013; 72 (10): 1639-45.
29. Sthoeger ZM, Sharabi A, Zinger H, Asher I, Mozes E. The tolerogenic peptide, hCDR1, down-regulates the expression of interferon-alpha in murine and human systemic lupus erythematosus. PLoS ONE 2013; 8 (3): e60394.
30. Landolt-Marticorena C, Bonventi G, Lubovich A, et al. Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus. Ann Rheum Dis 2009; 68 (9): 1440-6.
31. Panchanathan R, Choubey D. Murine BAFF expression is up-regulated by estrogen and interferons: implications for sex bias in the development of autoimmunity. Mol Immunol 2013; 53 (1-2): 15-23.
32. Jacob N, Guo S, Mathian A, et al. B cell and BAFF dependence of IFN-α- exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice. J Immunol 2011; 186 (8): 4984-93.
33. Bezalel S, Asher I, Elbirt D, Sthoeger ZM. Novel biological treatments for systemic lupus erythematosus: current and future modalities. IMAJ 2012; 14 (8): 508-14.
34. Zagury D, Le Buanec H, Mathian A, et al. IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model. Proc Natl Acad Sci USA 2009; 106 (13): 5294-9.
35. Mathian A, Amoura Z, Adam E, et al. Active immunization of human interferon α transgenic mice with a human interferon α kinoid induces antibodies that neutralise interferon α in sera from patients with systemic lupus erythematosus. Ann Rheum Dis 2011; 70 (6): 1138-43.
36. Petri M, Wallace DJ, Spindler A, et al. Sifalimumab, a human antiinterferon- α monoclonal antibody, in systemic lupus erythematosus: a phase 1 randomized controlled, dose-escalation study. Arthritis Rheum 2013; 65 (4): 1011-21.
37. Morimoto AM, Flesher DT, Yang J, et al. Association of endogenous antiinterferon- α autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63 (8): 2407-15.
38. Lauwerys BR, Hachulla E, Spertini F, et al. Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid. Arthritis Rheum 2013; 65 (2): 447-56.
39. Sullivan T, Atiee L, Bhagat W, et al. A novel toll like receptor antagonist for autoimmune and inflammatory diseases: safety and pharmocodynamics in a multiple-dose phase I clinical trial. Keystone Symphosia Meeting: Immunoregulatory Networks, 2011.
40. Pfizer, First safety study in humans of a single dose of CPG52364. Available from http://clinicalTrials.gov/ct2/show/NCT00547014 NLM identifier: NCT00547014.